NO892938L - Fremgangsmaate for lactonisering av mevinsyrer og analogerderav. - Google Patents

Fremgangsmaate for lactonisering av mevinsyrer og analogerderav.

Info

Publication number
NO892938L
NO892938L NO89892938A NO892938A NO892938L NO 892938 L NO892938 L NO 892938L NO 89892938 A NO89892938 A NO 89892938A NO 892938 A NO892938 A NO 892938A NO 892938 L NO892938 L NO 892938L
Authority
NO
Norway
Prior art keywords
lactonization
analogerative
tinic
acids
sources
Prior art date
Application number
NO89892938A
Other languages
English (en)
Other versions
NO892938D0 (no
NO172800C (no
NO172800B (no
Inventor
Laszlo R Treiber
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22827965&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO892938(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO892938D0 publication Critical patent/NO892938D0/no
Publication of NO892938L publication Critical patent/NO892938L/no
Publication of NO172800B publication Critical patent/NO172800B/no
Publication of NO172800C publication Critical patent/NO172800C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO892938A 1988-07-19 1989-07-17 Fremgangsmaate for lactonisering av mevinsyrer og analogerderav NO172800C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,475 US4916239A (en) 1988-07-19 1988-07-19 Process for the lactonization of mevinic acids and analogs thereof

Publications (4)

Publication Number Publication Date
NO892938D0 NO892938D0 (no) 1989-07-17
NO892938L true NO892938L (no) 1990-01-22
NO172800B NO172800B (no) 1993-06-01
NO172800C NO172800C (no) 1993-09-08

Family

ID=22827965

Family Applications (1)

Application Number Title Priority Date Filing Date
NO892938A NO172800C (no) 1988-07-19 1989-07-17 Fremgangsmaate for lactonisering av mevinsyrer og analogerderav

Country Status (26)

Country Link
US (1) US4916239A (no)
EP (1) EP0351918B1 (no)
JP (3) JPH0273078A (no)
KR (1) KR970011286B1 (no)
CN (1) CN1022831C (no)
AT (1) ATE111459T1 (no)
AU (1) AU609319B2 (no)
CA (1) CA1287639C (no)
CS (1) CS274640B2 (no)
CY (1) CY1813A (no)
DE (1) DE68918191C5 (no)
DK (1) DK173115B1 (no)
ES (1) ES2058475T3 (no)
FI (1) FI92695C (no)
HK (1) HK136894A (no)
HR (1) HRP930685B2 (no)
HU (2) HU202511B (no)
IE (1) IE64304B1 (no)
IL (1) IL90925A (no)
LV (1) LV11033B (no)
NO (1) NO172800C (no)
NZ (1) NZ229879A (no)
PT (1) PT91191B (no)
SI (1) SI8911362A (no)
YU (1) YU47492B (no)
ZA (1) ZA895458B (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
GB9007738D0 (en) * 1990-04-05 1990-06-06 British Bio Technology Compounds
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5250435A (en) * 1991-06-04 1993-10-05 Merck & Co., Inc. Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
AU660132B2 (en) * 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
EP0680320B1 (en) * 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
IN186879B (no) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
IN186880B (no) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
ZA9810764B (en) * 1998-04-22 1999-08-13 Ranbaxy Lab Ltd An improved process of lactonization in the preparation of statins.
CA2240983A1 (en) 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
HUP0103021A3 (en) * 1998-12-10 2002-04-29 Kaneka Corp Process for producing simvastatin derivatives
SK282679B6 (sk) * 1999-04-16 2002-11-06 Biotika, A. S. Spôsob izolácie lovastatínu z vyfermentovanej pôdy
HUP0103611A2 (en) * 1999-06-29 2009-10-28 Kaneka Corp Process for selective lactonization
EP1228057A2 (en) * 1999-10-27 2002-08-07 Merck & Co., Inc. Lactonization process
JP2003525935A (ja) 2000-03-03 2003-09-02 ビオガル ジョジセルジャール アール テー． 低下したレベルの二量体不純物を伴うロバスタチン及びシンバスタチンの精製方法
NL1017548C2 (nl) * 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
US6797831B2 (en) * 2001-05-18 2004-09-28 Aurobindo Pharma Limited Process for lactonization to produce simvastatin
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
KR100502834B1 (ko) * 2002-03-25 2005-07-20 보령제약 주식회사 개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
CA2480325A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR20050098313A (ko) 2003-02-11 2005-10-11 플러스 케미칼스 비.브이. 제어된 범위의 심바스타틴 이량체 함량을 갖는심바스타틴의 제조 방법
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
DE602004017784D1 (de) * 2004-03-30 2008-12-24 Lupin Ltd Verbessertes verfahren zur herstellung von 4-hydroxypyran-2-onderivaten
US7678927B2 (en) * 2004-09-08 2010-03-16 Jubilant Organosys Limited Process for lactonization in the preparation of statins
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
WO2006059346A2 (en) * 2004-12-01 2006-06-08 Morepen Laboratories Limited An improved process for lactonization to produce highly pure statins
KR20070085874A (ko) 2004-12-09 2007-08-27 머크 앤드 캄파니 인코포레이티드 에스트로겐 수용체 조절제
EP1855674B1 (en) 2005-03-02 2014-07-16 Merck Sharp & Dohme Corp. Composition for inhibition of cathepsin k
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US20070117996A1 (en) * 2005-11-21 2007-05-24 Srinivasulu Gudipati Process for preparing simvastatin
PE20071162A1 (es) * 2005-12-21 2007-11-30 Schering Corp Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
WO2007075702A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
LT2010528T (lt) 2006-04-19 2017-12-27 Novartis Ag 6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090048335A1 (en) * 2007-08-17 2009-02-19 Venkata Naga Mandava Process for preparing simvastatin
US8354446B2 (en) 2007-12-21 2013-01-15 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (SARMs) and uses thereof
US8414958B2 (en) * 2008-02-27 2013-04-09 Thommen Medical Ag Implant and method for the manufacture thereof
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
CN101704808A (zh) 2009-11-20 2010-05-12 西南合成制药股份有限公司 制备他汀类化合物的内酯化方法
CN104098537A (zh) * 2009-11-20 2014-10-15 北大医药股份有限公司 制备他汀类化合物的内酯化方法
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
DK2606134T3 (da) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9393224B2 (en) 2011-08-26 2016-07-19 Osaka University Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2597092A1 (en) 2011-11-24 2013-05-29 Sterling Biotech Limited A process for purification of lovastatin
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US9458181B2 (en) 2013-10-08 2016-10-04 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4077282A4 (en) 2019-12-17 2023-11-08 Merck Sharp & Dohme LLC PRMT5 INHIBITORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81703B (en) * 1980-02-04 1982-09-29 Merck & Co Inc New antihypercholesterolemic compounds,intermediates and processes
JPS5948418A (ja) * 1982-09-10 1984-03-19 Sankyo Co Ltd 高血清過酸化脂質血症治療剤
US4582915A (en) * 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US4611068A (en) * 1984-11-19 1986-09-09 Merck Frosst Canada, Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4611067A (en) * 1985-01-31 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4772626A (en) * 1986-01-31 1988-09-20 Merck & Co., Inc. Antihypercholesterolemic compounds
PT85109A (en) * 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4857546A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof

Also Published As

Publication number Publication date
ES2058475T3 (es) 1994-11-01
HRP930685B2 (hr) 2006-11-30
NZ229879A (en) 1991-12-23
IE64304B1 (en) 1995-07-26
HU202511B (en) 1991-03-28
JP2718422B2 (ja) 1998-02-25
US4916239A (en) 1990-04-10
PT91191A (pt) 1990-02-08
HUT50804A (en) 1990-03-28
DK173115B1 (da) 2000-01-31
CS435489A2 (en) 1990-12-13
CN1039420A (zh) 1990-02-07
AU609319B2 (en) 1991-04-26
FI92695B (fi) 1994-09-15
HU210533A9 (en) 1995-04-28
HK136894A (en) 1994-12-09
HRP930685B1 (en) 1999-06-30
CY1813A (en) 1995-10-20
IE892324L (en) 1990-01-19
FI893363A (fi) 1990-01-20
KR970011286B1 (ko) 1997-07-09
JPH0575752B2 (no) 1993-10-21
FI92695C (fi) 1994-12-27
SI8911362A (en) 1997-02-28
NO892938D0 (no) 1989-07-17
FI893363A0 (fi) 1989-07-11
LV11033A (lv) 1996-02-20
YU47492B (sh) 1995-10-03
HRP930685A2 (en) 1998-06-30
DK354189A (da) 1990-01-22
CS274640B2 (en) 1991-09-15
ATE111459T1 (de) 1994-09-15
EP0351918A1 (en) 1990-01-24
DE68918191D1 (de) 1994-10-20
IE892324A1 (en) 1991-06-19
YU136289A (en) 1991-02-28
DE68918191T2 (de) 1995-03-02
IL90925A0 (en) 1990-02-09
JPH07196642A (ja) 1995-08-01
CN1022831C (zh) 1993-11-24
JPH09188672A (ja) 1997-07-22
CA1287639C (en) 1991-08-13
KR910002828A (ko) 1991-02-26
PT91191B (pt) 1995-03-01
AU3824089A (en) 1990-01-25
EP0351918B1 (en) 1994-09-14
NO172800C (no) 1993-09-08
JPH0273078A (ja) 1990-03-13
DE68918191C5 (de) 2005-06-09
LV11033B (en) 1996-06-20
DK354189D0 (da) 1989-07-18
NO172800B (no) 1993-06-01
ZA895458B (en) 1990-03-28
IL90925A (en) 1993-04-04

Similar Documents

Publication Publication Date Title
NO892938L (no) Fremgangsmaate for lactonisering av mevinsyrer og analogerderav.
HUT63419A (en) Process for producing mercaptoacetamide derivatives of pyrrolo-, pyrido- and oxazinobenzazepine having encephalinase- and angiotensin-converting enzyme-inhibiting activity
MX9203768A (es) Inhibidores novedosos de reductasa 3-hidroxi-metilglutaril-coenzima a.
ATE179169T1 (de) Prostaglandinanaloge
NO924690L (no) Fremgangsmaate for fremstilling av mono-n-substituerte tetraazakrocykluser
PT88364A (pt) Process for preparing novel hmg-coa reductase inhibitors
DE69001650D1 (de) Phenylsulfon-derivate.
DE69025817D1 (de) 3-Keto-HMG-CoA Reduktase-Inhibitoren
DK196489A (da) Carbamatderivater samt en fremgangsmaade til fremstilling heraf

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees